Cognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.
Financial Conflict of Interest Policy under 42 CFR Part 50, Subpart F
Compliance program
NeuroNascent, IncFounded by neuroscientist Judith Kelleher-Andersson, NeuroNascent is a privately held biotechnology company developing oral small-molecule therapies designed to stimulate the brain’s own neuron regeneration. Its lead candidate, NNI-362, has completed Phase 1a safety testing in healthy older adults and is being advanced for Alzheimer’s and Parkinson’s disease, while the company’s patented discovery platform also supports programs in other neurological disorders. The Clarksville, Maryland company is led by a team with deep experience in central nervous system drug development.CLARKSVILLE, MD
Galimedix Therapeutics, IncGalimedix Therapeutics is a Phase 2 clinical-stage biotechnology company developing oral and topical small-molecule therapies for neurodegenerative diseases of the eye and brain. Its lead candidate, GAL-101, targets misfolded amyloid beta before toxic oligomers form and is being studied as an eye drop for geographic atrophy, an advanced form of dry age-related macular degeneration. The company’s approach also supports planned development in glaucoma and Alzheimer’s disease, with ophthalmology commercialization backed by Théa Open Innovation.KENSINGTON, MD
IGC Pharma, IncFrom its Potomac headquarters, IGC Pharma develops investigational therapies and AI tools for Alzheimer’s disease and related dementias. Its lead candidate, IGC-AD1, is being evaluated in the Phase 2 CALMA trial for agitation associated with Alzheimer’s dementia, while the company’s MINT-AD and aha™ platforms apply artificial intelligence to risk prediction and research-data harmonization. IGC Pharma operates an integrated international organization with manufacturing and processing in Vancouver, Washington, clinical research in Colombia, and accounting and analytics in India.POTOMAC, MD
Clene Nanomedicine, IncClene Nanomedicine is a clinical-stage biopharmaceutical company co-founded in 2013 and focused on developing treatments for neurodegenerative disease. Its patented electro-crystal-chemistry process produces clean-surfaced nanocrystals, including the investigational gold-based candidate CNM-Au8 for people living with ALS.NORTH EAST, MD